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Abstract
Increased oxidative stress occurs in the lungs and systemically in COPD, which plays a role in
many of the pathogenic mechanisms in COPD. Hence, targeting local lung and systemic oxidative
stress with agents that modulate the antioxidants/redox system or boost endogenous antioxidants
would be a useful therapeutic approach in COPD. Thiol antioxidants (N-acetyl-L-cysteine and N-
acystelyn, carbocysteine, erdosteine, and fudosteine have been used to increase lung thiol content.
Modulation of cigarette smoke induced oxidative stress and its consequent cellular changes have
also been reported to be effected by synthetic molecules, such as spin traps (α-phenyl-N-tert-butyl
nitrone), catalytic antioxidants (superoxide dismutase [ECSOD] mimetics), porphyrins, and lipid
peroxidation and protein carbonylation blockers/inhibitors (edaravone and lazaroids/tirilazad).
Pre-clinical and clinical trials have shown that these antioxidants can reduce oxidative stress,
affect redox and glutathione biosynthesis genes, and pro-inflammatory gene expression. In this
review the approaches to enhance lung antioxidants in COPD and the potential beneficial effects
of antioxidant therapy on the course of the disease are discussed.
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Introduction
The lungs due to their high blood supply and large surface area are constantly in a high-
oxygen environment. In addition the lung epithelium is also constantly exposed to oxidants
generated endogenously during respiration from mitochondrial electron transport, from
activated inflammatory cells that influx into the lungs and exogenously from cigarette
smoke (CS) and air pollutants, such as ozone, nitrogen dioxide, and combustion particulates,
as a result of its exposure to the environment.
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When the the resident antioxidants are insufficient or fail to upregulate sufficiently to
neutralize an increased oxidant burden oxidative stress occurs. Reactive oxygen species
(ROS), either non-radical, such as hydrogen peroxide (H2O2) or oxygen radicals, such as
superoxide anion (O2•−) and the hydroxyl radical (•OH) that are highly unstable species with
unpaired electrons are capable of initiating oxidation, and together with reactive nitrogen
species (RNS) result in a variety of adverse consequences ranging from cell necrosis,
senescence, apoptosis, autophagy, lipid peroxidation and protein carbonylation,
inflammatory responses, epigenetic changes, remodeling of extracellular matrix and blood
vessels, endothelial dysfunction, inactivation of antiproteases, mucus hypersecretion, and
impaired tissue repair [1]. COPD is also a disease associated aging, which has been shown
to result in a decline in the endogenous antioxidant defenses resulting in less protection
against oxidative stress. The pathogenesis of COPD involves several processes as described
above. All of these processes are intimately associated with oxidative stress (Fig 1) [1•].
Rationale for antioxidants therapy in COPD
Cigarette smoke is the main etiological factor in pathogenesis of COPD and contains more
than 1015-17 oxidant/free radical molecules per puff [2], which increases oxidant burden in
the lungs in current smokers. Since many of the pathogenic mechanisms in COPD involve
oxidative stress, oxidative stress should be a target for treatment that may have an effect on
underlying disease processes in this condition. This could be achieved either by decreasing
the generation of oxidants or by enhancing antioxidants.
Clinical testing of several small-molecular weight compounds that target oxidant/redox
signaling, or quench oxidants and reactive aldehydes are currently being conducted.
Antioxidant agents, such as thiol compounds/donors and their analogs (GSH and mucolytic
drugs, such as N-acetyl-L-cysteine, carbocysteine, erdosteine, and fudosteine all effectively
scavenge/detoxify free radicals/oxidants, increase intracellular thiol levels and control NF-
κB activation, and hence inhibit inflammatory gene expression. Enzyme mimetics that can
either enhance the expression/activity of the antioxidant enzymes or mimic their function are
currently being developed. In the ensuing sections, we discuss the beneficial effects of a
wide variety of pharmacological antioxidants that are potential therapeutic agents in COPD
(Table 1). The efficacy of these antioxidant molecules can be assessed by i) improving
symptoms or function, ii) modifying the course of the disease by reducing the decline in
lung function or decreasing exacerbation frequency, and iii) decreasing the oxidant burden
or biomarkers of oxidative stress in patients with COPD.
Small molecule thiol antioxidants
N-acetyl-L-cysteine (NAC)
NAC is an acetyl derivative of the amino acid, cysteine, and is strong reducing agent (Table
1). NAC is a mucolytic agent that reduces mucus viscosity, thereby improving mucociliary
clearance. NAC is deacetylated to cysteine in the gastrointestinal tract which serves as
precursor of glutathione. By reducing disulfide bonds, NAC is able to neutralize oxidant
species. Since NAC can reduce intracellular cystine to cysteine, it can increase intracellular
GSH in vivo in lungs.
NAC is the most widely studied thiol molecule in vitro and in vivo. In preclinical studies
oral administration of NAC has been shown to attenuate elastase-induced emphysema in rats
[3]. NAC also protects against the oxidation of Z α1-antitrypsin by cigarette smoke in an
early-onset emphysema mouse model [4]. In view of the importance of glutathione (GSH) as
an antioxidant in the lungs, NAC has mainly been used to enhance lung GSH in patients
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with COPD [5]. Clinical studies of the beneficial effects of NAC and other thiols in patients
with COPD have yielded mixed results (Table 2) [5-19].
A randomized, double-blind, placebo controlled trial of 6-month of 600 mg NAC, twice
daily reduced various plasma and BAL fluid oxidative biomarkers in smokers [18]. NAC
600 mg twice daily for 2 months was shown to reduce the oxidant burden in the airways of
stable COPD patients [15], and was associated with reduced risk of exacerbations and
improved lung symptoms in patients with chronic bronchitis [10]. Another study has shown
a beneficial effect of NAC on muscle function by demonstrating an increase in quadriceps
endurance time in severe COPD patients associated with a decrease in markers of systemic
oxidative stress [20].
A Cochrane systematic review and other meta-analyses [9] showed a decrease in number of
exacerbations by 29% . However, the large multicenter trial, the Bronchitis Randomized on
NAC Cost-Utility Study (BRONCUS) showed no effect on exacerbation frequency or
decline in FEV1 [7••]. However, this study showed a reduction in overinflation and in
exacerbation frequency in patients with COPD not treated with inhaled glucocorticoids [7].
NAC has to be deacetylated in the gut to cysteine to act as a precursor of GSH and as such is
not very bioavailable to increase GSH. Thus further studies may be warranted using NAC at
higher doses (1200 or 1800 mg/day) or using other thiol agents that have a greater
bioavailability in order to observe any clinical benefit in COPD.
Carbocysteine
S-carboxymethylcysteine (carbocysteine or S-CMC), which has mucoactive, antioxidant and
anti-inflammatory properties, is a thiol derivative of amino-acid, L-cysteine (Table 1). Oral
preparations of carbocysteine both as S-CMC and its lysine salt (S-CMC-lys) are available.
The lysine residue in S-CMC-lys is cleaved in the gastrointestinal tract to yield the active
drug S-CMC. The mucoactive action of carbocysteine differs from other thiol mucolytics,
such as NAC and erdosteine since it increases the sialomucin content which influences the
rheological properties of mucus via the inhibition of kinins [21]. Carbocysteine also
facilitates muco-ciliary clearance velocity, particularly in patients with chronic bronchitis
who have slow clearance before treatment [21].
In preclinical studies Carbocysteine has been shown to protect against emphysema induced
by cigarette smoke in rats [22]. Treatment of COPD patients with S-CMC-Lys for a 6-
months significantly decreased the levels of the lipid peroxidation product 8-isoprostane and
the pro-inflammatory cytokine: IL-6, indicating that the drug has both antioxidant and anti-
inflammatory properties [23].
Due to its ability to reduce bacterial respiratory tract infections in COPD [24-25], it has been
suggested that carbocysteine may act via the inhibition of pathogen adherence to cells. This
is supported by in vitro studies, where carbocysteine treatment has been shown to reduce in
the adherence of Moraxella catarrhalis (a bacteria commonly found in exacerbations of
COPD) to pharyngeal epithelial cells, of both healthy subjects and those with chronic
bronchitis, when compared to placebo treated group [24]. Similarly, carbocysteine can
significantly reduce attachment of Streptococcus pneumoniae to pharyngeal epithelial cells
[25]. Carbocysteine could also reduce the frequency of common colds and associated
exacerbations in COPD patients, a property that has been attributed to its ability to decrease
ICAM-1 expression in the respiratory tract [26].
Clinical studies of carbocysteine in COPD patients are now available (Table 2) [17,26-34].
The PEACE study investigated the effect of treatment of 709 Chinese COPD subjects for 3
Rahman and MacNee Page 3
Curr Opin Pharmacol. Author manuscript; available in PMC 2013 September 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
years with carbocysteine (250 mg t.d.s) and found that COPD patients treated with
carbocysteine experienced fewer numbers of exacerbations per year [17••]. Of note the
majority of these patients were not receiving corticosteroids.
Erdosteine
Erdosteine is a mucoactive thiol antioxidant (Table 1). The drug was originally used as a
mucolytic agent and acts by breaking the disulfide bonds of mucus glycoproteins, affecting
the physical properties of the mucus, thus leading to increased mucus clearance [35]. It also
has antioxidant, anti-inflammatory, and antibacterial activity.
‘Equalife’, a randomized, placebo-controlled clinical study involving oral administration of
300 mg erdosteine twice daily for 8 months produced a significant improvement in quality
of health and a reduction in exacerbations compared to placebo [16]. Erdosteine has also
been reported to be beneficial in patients suffering from repeated, prolonged or severe
exacerbations of COPD [36-37]. In one study treatment with Erdosteine reduced the rate of
severe exacerbations requiring hospital admission [35]. Administration of erdosteine 300 mg
twice a day for 7 - 10 days also improved symptoms and reduced the duration of
hospitalization in patients presenting with an exacerbation of COPD [38]. Erdosteine (600
mg/day) treatment with procysteine has been shown to improve cigarette smoke-induced
ROS production by alveolar macrophages and the levels of the chemotactic cytokines IL-6
and IL-8 in bronchial secretions of current smokers with COPD [37]. The anti-inflammatory
properties of erdosteine have also been shown by a reduction in the levels of
proinflammatory eicosanoids in blood in COPD patients [39].
Fudosteine
Fudosteine, [(−)-(R)-2-amino-3-(3-hydroxypropylthio)] propionic acid (Table 1), has been
used and a mulcolytic and antioxidant. It has greater bioavailability than NAC and acts as an
antioxidant by increasing intracellular cysteine levels. In preclinical studies, fudosteine
inhibits mucin hypersecretion by downregulating MUAC5AC gene expression [40].
Expression levels of p-p38 MAPK and p-ERK in rat in vivo and of p-ERK in a bronchial
epithelial cell line in vitro are decreased by fudosteine [40]. Fudosteine has also been shown
to inhibit peroxynitrite-induced airway nitrative stress in lung epithelial cells by direct
scavenging of this free radical [41]. Hence, fudosteine may be used in the treatment of
chronic respiratory diseases, such as bronchial asthma, chronic bronchitis, COPD, and
bronchiectasis as a mucoactive agent [40,42].
Nrf2 activators
Nuclear factor erythroid 2 p45-related factor 2 (Nrf2) is a basic-leucine zipper (b-ZIP)
transcription factor present in the cytoplasm of normal cells that plays an important
protective role against electrophiles and ROS. In response to oxidative and electrophilic
stresses, Nrf2 detaches from its cytosolic inhibitory subunit, Kelch-like ECH-associated
protein 1 (Keap1), and translocates into the nucleus where it binds to the antioxidant
response element (ARE) of target genes [43-45]. Nrf2 regulates almost all the antioxidants
and phase II cytoprotective genes, such as NAD(P)H/quinone oxidoreductase 1(NQO1),
glutamate cysteine ligase modifier subunit (GCLM), glutamate cysteine synthase,
glutathione peroxidase (GPx), and several members of the glutathione S-transferase family
[43].
Studies with Nrf2 null mice have shown greater susceptibility of these mice to cigarette
smoke-induced emphysema compared with wild-type mice [46-47] indicating a protective
role for Nrf2. Loss of Nrf2 positive regulator DJ-1 (stabilizer of Nrf2) and posttranslational
modifications of the Keap1–Bach1 equilibrium results in downregulation of Nrf2 in the
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lungs of patients with COPD [48-51•]. The Nrf2 activator CDDO-imidazolide (Table 1) has
been shown to protect mice against CS-induced emphysema [45•]. Activation of Nrf2 by
sulforaphane (present in broccoli and cruciferous vegetables) can also have a beneficial
effect in attenuating some of biochemical alterations that occur in smokers/COPD [52••].
Novel compounds which are potent activators of Nrf2 or which stabilize Keap1/DJ-1/Maf
proteins can be developed. Chalcones have anti-inflammatory effects due to their ability to
inhibit the NF-κB pathway [53-54] and simultaneously activate the Nrf2/ARE pathway thus
inducing phase II detoxifying enzyme expression [55]. Currently, various derivatives of
chalcones are being developed with a potential therapeutic role in COPD [56•]. However,
the pharmacokinetics, bioavailability, and toxicity of these compounds in the lungs are as
yet unknown.
Lipid peroxidation and protein carbonylation inhibitors/blockers
Edaravone (MC-186)
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a potent free-radical and protein
carbonyl scavenger and inhibitor of lipid peroxidation [57-58]. Protein carbonylation and
carbonyl stress via aldehydes occur in COPD and hence edaravone has the potential to
protect the lungs against the effects of these oxidative products [59-60]. Edaravone has been
shown to ameliorate the lung injury, inflammation, oxidative stress, and mortality induced
by intestinal ischemia/reperfusion in rats [61]. Given the antioxidant, anti-inflammatory
properties of edaravone, it has potential as a treatment in COPD.
Lazaroids
Lazaroids (21-aminsteroids, U75412E or tirilazad mesylate) are a group of non-
glucocorticoid analogues of methyl-prednisolone which are able to penetrate hydrophobic
regions of the cell membrane, specifically to prevent peroxidation of membrane lipids [62].
The protective effects of lazaroids have been reported in many animal models of lung injury
[63-64], including the effects of cigarette smoke [65]. Their protective effect is mainly by
inhibition of lipid peroxidation. In a smoke-induced lung injury model lazaroids inhibited
the formation of free radicals and the release of tumor necrosis factor-α by alveolar
macrophages [66-67]. Further studies are required to evaluate the efficacy of lazaroids as
therapeutic strategy in COPD.
Enzymatic antioxidants
Cellular ROS can be effectively neutralized by antioxidant enzymes, such as superoxide
dismutase (SOD), catalase, and glutathione peroxidase, whose expression and activities are
altered in various disease conditions involving oxidative stress. Restoration of altered
antioxidant enzyme activity can be achieved by small molecules possessing catalytic
properties which can mimic the activity of the enzyme.
SOD mimetics
SOD mimetics are of three classes. The first class includes several manganese-based
macrocyclic ligands, such as M40401, M40403, and M40419 [68-69]. The second class
includes manganese-metaloporphyrins, such as AEOL-10113 and AEOL-10150 [70-71],
and the third category is comprised of “Salens” (manganese based SOD mimetic). Salens
have an additional advantage as they are also reported to have catalase-like activity, and
therefore can also neutralize H2O2, and ONOO− [72]. Until now only the second class of
SOD mimetics has been studied in animal models of airway inflammation. A significant
decrease in the lungs of markers of oxidative stress, and emphysema has been observed in
response to the SOD mimetic M40419 in animal models [68]. The SOD mimetic
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AEOL10150 has also been shown to inhibit cigarette smoke-induced lung inflammation in
the rat and to decreased lipid peroxidation and the generation of ONOO− [71]. The ability of
recombinant SOD treatment to prevent neutrophil influx into the lungs and decrease IL-8
release induced by cigarette smoking [73], indicates its potential as an antioxidant an anti-
inflammatory in COPD.
Broad antioxidant properties and the ability to scavenge superoxide, lipid peroxides,
ONOO-, and H2O2 have been attributed to the metalloporphyrin-based catalytic antioxidant,
MnTE-2-PyP [Manganese (III) Meso-Tetrakis-(NMethlypyridinium-2-yl) porphyrin]
[74-76]. Administration of MnTE-2-PyP has been shown to decrease inflammation and
injury induced by wide variety of factors [77-78]. Its anti-inflammatory properties have been
attributed to its ability to reduce NF-κB signaling [77]. Therefore, these compounds may
have potential for therapeutic use in COPD.
Extracellular superoxide dismutase (ECSOD or SOD3) is highly expressed in lungs and is
located in the extracellular matrix in the junctions of airway epithelial cells, the surface of
airway smooth muscle, and the lining of blood vessels of the lungs [79]. SOD3 directly
scavenges O2 •−, and may therefore play an important role in protecting against oxidative
lung damage. SOD3 protects against cigarette smoke/elastase induced mouse models of
emphysema via reduction of oxidative ECM fragmentation and oxidative posttranslational
modifications of elastin fragments (leading to autoantibody production) [80••]. A recent
study has revealed that SOD3 can decrease CS-induced oxidative stress in mouse
macrophages [81]. SOD3 also attenuates lung inflammation and emphysema by decreasing
oxidative fragmentation of ECM, such as heparin sulfate and elastin [80]. Therefore, the
development of pharmacological mimetics to replenish/augment SOD3 in the lung would be
a rational therapeutic intervention for COPD/emphysema.
Glutathione peroxidase (GPx) mimetics
Ebselen is a selenium-based organic complex that mimics the activity of glutathione
peroxidase. Ebselen is strong antioxidant and is also known to have strong neutralizing
effect against the peroxynitrite radical [82]. Ebselen inhibits the activation of NF-κB/AP-1,
and hence the expression of pro-inflammatory genes in human leukocytes treated with
peroxynitrite. Ebselen has been shown in vivo in animal models to prevent LPS-induced
airway inflammation [83-84]. However, no reports are available as the protective effect of
ebselen against cigarette smoke-induced lung inflammation.
Spin traps and iNOS inhibitors
Spin traps are chemical agents which can quench free radicals to form measurable stable end
products. Most spin traps have a nitrone- or nitroxide-nucleus and are derivatives of these
moieties. Spin traps have been widely used for in vitro studies and their therapeutic effects
in vivo have also been investigated in models of lung inflammation using α-phenyl-N-tert-
butyl nitrone [85]. Early spin traps had extremely small half lives and generated toxic
hydroxyl radicals on decay. This problem has now been overcome by the introduction of
electron withdrawing moieties around the core pyrroline ring [86]. Isoindole-based nitrones
[87] and azulenyl-based nitrones [88], such as STANZ have strong antioxidant properties
and can inhibit lipid peroxidation in vitro. Phenyl-base nitrone spin trap (PBN) derivatives,
such as NXY-059 (PBN-2,4,disulfonate), have been shown to have benefits in a wide
variety of animal models of lung diseases (http://www.nitrone.com/).
Recent studies have suggested that inhibition of iNOS by various chemical inhibitors [N(6)-
(1-iminoethyl)-L-lysine (L-NIL), G-nitro-L-arginine-methyl ester or L-NAME attenuated
animal models of emphysema [89-91]. It is possible that selective inhibition of iNOS [90•]
Rahman and MacNee Page 6
Curr Opin Pharmacol. Author manuscript; available in PMC 2013 September 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
along with supplementation of other antioxidants may provide a strategy in the management
of COPD.
Redox sensors: Enzymatic
Thioredoxin
Thioredoxin (Trx) and redox effector factor-1 (Ref-1), belong to oxidoreductase family of
redox sensors. Trx, is primarily bound to proteins, such as hepatopoietin [92] and the
apoptosis signal regulating kinase (ASK-1) [93], that are released from these complexes
during oxidative stress [92]. After dissociation, Trx reduces a key thiol group within the
p65/NF-κB subunit leading to transcriptional activation [94]. Inhibiting Trx (in the nucleus)
with MOL-294 (a small molecular weight inhibitor of Trx), blocks nuclear activation of both
NF-κB and AP-1-dependent transcription that results in diminished neutrophil influx and
TNF-α production in an animal model [95]. Activation of Trx by synthetic small molecules
attenuated oxidative stress [96]. Overexpression of thioredoxin-1 (Trx-1), primarily due to
its antioxidant property attenuates CS-mediated oxidative stress and emphysema [97•],
however the effects in COPD still remain to be investigated.
Conclusions
Increased oxidative/carbonyl stress occurs in COPD as is thought to be an important
mechanism in the pathogenesis of this condition. Targeting oxidative stress with
pharmacological antioxidants or boosting the endogenous levels of antioxidants is likely to
be beneficial as a treatment in COPD. Antioxidant therapy may affect important outcomes in
COPD, such as overcoming steroid resistance, mucus hypersecretion, inflammation, and
ECM remodeling. Several small molecule antioxidant compounds have been investigated in
pre-clinical and clinical trials. Although thiol antioxidant treatments have shown promising
effects in targeting ROS and adverse oxidant-mediated cellular responses, development of
novel wide-spectrum small molecule antioxidants with a good bioavailability and potency
are needed for clinical trials for COPD. However, the clinical trials have been limited and
there is a lack of information on pharmacokinetics, bioavailability, toxicity, and absorption
of various exogenous antioxidants and activators of endogenous antioxidants.
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Highlights
Cigarette smoke causes oxidative stress in COPD.
Antioxidants can modulate intracellular redox system.
Thiols, enzyme mimetics, spin traps, and redox sensors are therapeutic agents.
Lipid peroxidation and protein carbonylation inhibitors block oxidative processes.
Antioxidants have pharmacological beneficial effects in management of COPD.
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Figure 1. Consequences of oxidative stress in COPD
The pathogenesis of COPD involves several oxidative stress-induced cellular and molecular
processes. Oxidative stress imposed by inhaled oxidants or produced from endogenous
sources can lead to depletion of antioxidants. An oxidant/antioxidant imbalance in favor of
oxidants leads to activation of various cellular processes which result in cellular and
molecular events involved in pathogenesis of COPD.
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Table 1
A list of thiol antioxidants and Nrf2 activators
Antioxidant Structure
N-acetyl-L-cysteine
Erdosteine
Fudosteine
Carbocysteine
(S-Carboxymethyl-L-cysteine)
Sulforaphane
Triterpenoids-
2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic
acid (CDDO)
Other analogs of CDDO
-1[2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-
oyl]imidazole (CDDO-Im)
Dihydro-CDDO-Trifluoroethyl Amide
CDDO Methyl Amide
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du
ct
io
n 
in
 d
ay
s o
f d
isa
bi
lit
y 
(0.
65
 da
y p
er
pa
tie
nt
 p
er
 m
on
th
) a
nd
 29
% 
red
uc
tio
n i
n
ex
ac
er
ba
tio
ns
.
[8
-9
]
Sy
ste
m
at
ic
 C
oc
hr
an
e
re
v
ie
w
 o
f r
an
do
m
iz
ed
,
co
n
tr
ol
le
d 
tri
al
s; 
11
 o
f 3
9
re
tr
ie
ve
d 
tri
al
s
N
A
C
U
se
 o
f v
al
id
at
ed
 sc
or
e 
to
ev
al
ua
te
 th
e 
qu
al
ity
 o
f
ea
ch
 st
ud
y
9 
tri
al
s s
ho
w
ed
 p
re
ve
nt
io
n 
of
 ex
ac
er
ba
tio
n 
an
d 
5
o
f w
hi
ch
 a
dd
re
ss
ed
 im
pr
ov
em
en
t o
f s
ym
pt
om
s
co
m
pa
re
d 
w
ith
 3
4.
6%
 o
f p
at
ie
nt
s r
ec
ei
vi
ng
pl
ac
eb
o.
[1
0]
M
et
a-
an
al
ys
is 
of
pu
bl
ish
ed
 tr
ia
ls
N
A
C
A
ss
es
s p
os
sib
le
pr
op
hy
la
ct
ic
 b
en
ef
its
 o
f
pr
ol
on
ge
d 
tre
at
m
en
t
23
%
 d
ec
re
as
e 
in
 n
um
be
r o
f a
cu
te
 e
xa
ce
rb
at
io
ns
[1
1]
-
N
A
C 
(60
0 m
g/d
, 5
da
ys
 a
nd
 6
00
 m
g,
3/
d.
 5
da
ys
)
Ef
fe
ct
 o
f N
A
C 
on
 G
SH
an
d 
cy
ste
in
e
In
cr
ea
se
 o
f G
SH
 a
t d
ay
 5
 an
d 
cy
ste
in
e (
pla
sm
a)
at
 d
ay
 5
[5
]
-
N
A
C 
(60
0 m
g
o
n
ce
 a
 d
ay
 fo
r 1
2
m
o
n
th
s)
Ef
fe
ct
 o
f N
A
C 
on
 H
2O
2
an
d 
TB
A
RS
 in
 E
BC
N
o 
ch
an
ge
 in
 T
BA
RS
 le
ve
ls
R
ed
uc
e 
H
2O
2 
le
ve
ls
[1
2]
-
N
A
C 
(60
0 m
g/d
,
7d
ay
s)
Ef
fe
ct
 o
f N
A
C 
on
 F
EV
1,
br
ea
th
le
ss
ne
ss
N
o 
di
ffe
re
nc
e 
co
m
pa
re
d 
to
 p
la
ce
bo
 g
ro
up
[1
3]
-
N
A
C 
(60
0 m
g /
d)
Ef
fe
ct
 o
f N
A
C 
on
cy
to
ki
ne
 a
nd
 e
xh
al
ed
br
ea
th
 c
on
de
ns
at
e 
(E
BC
)
D
ec
re
as
e 
IL
-8
 a
nd
 E
CP
 le
ve
l i
n 
N
A
C 
gr
ou
p
[1
4]
-
N
A
C 
(60
0 m
g ×
2/
d 
× 
2 
m
on
th
s)
Ef
fe
ct
 o
f N
A
C 
on
 H
2O
2
D
ec
re
as
e 
H
2O
2 
le
ve
l i
n 
N
A
C 
gr
ou
p
[1
5]
EQ
UA
LI
FE
 st
ud
ies
V
ec
tri
ne
-th
io
l
co
m
po
un
d,
 3
00
m
g
b.
i.d
 fo
r m
on
th
s
Ef
fe
ct
 o
n 
ex
ac
er
ba
tio
n
ra
te
, h
os
pi
ta
liz
at
io
n,
 lu
ng
fu
nc
tio
n 
an
d 
qu
al
ity
 o
f l
ife
D
ec
re
as
ed
 e
xa
ce
rb
at
io
ns
 a
nd
 fe
w
er
 d
ay
s i
n
ho
sp
ita
l. 
N
o 
lo
ss
 o
f l
un
g 
fu
nc
tio
n 
an
d
im
pr
ov
em
en
t i
n 
he
al
th
-re
la
te
d 
qu
al
ity
 o
f l
ife
.
[1
6]
Sm
al
l s
ca
le
 U
K
 st
ud
ie
s
Ca
rb
oc
ys
te
in
e
Ef
fe
ct
 o
f 2
.2
5–
3.
00
 g
ca
rb
oc
ys
te
in
e 
da
ily
 a
lo
ng
w
ith
 p
la
ce
bo
 in
 c
hr
on
ic
br
on
ch
iti
s
H
et
er
og
en
eo
us
 re
su
lts
 o
n 
al
te
ra
tio
ns
 in
 F
EV
1,
pe
ak
 fl
ow
 ra
te
 a
nd
 d
ys
pn
ea
 sc
or
es
[2
7-
30
]
A
n 
Ita
lia
n 
m
ul
ti-
ce
nt
er
,
pr
os
pe
ct
iv
e,
 d
ou
bl
e-
bl
in
d
R
CT
 in
vo
lv
in
g 
66
2
o
u
tp
at
ie
nt
s w
ith
 a
 c
hr
on
ic
Ca
rb
oc
ys
te
in
e
Ef
fe
ct
 o
f 2
.7
 g
 S
-C
M
C-
Ly
s o
nc
e 
da
ily
 fo
r 6
m
o
n
th
s o
n 
CO
PD
 p
at
ie
nt
s
N
o 
sig
ni
fic
an
t d
iff
er
en
ce
 in
 b
as
el
in
e 
FE
V
1
be
tw
ee
n 
th
e 
gr
ou
ps
. M
ea
n 
tim
e 
to
 fi
rs
t
ex
ac
er
ba
tio
n 
w
as
 si
gn
ifi
ca
nt
ly
 p
ro
lo
ng
ed
 a
nd
sig
ni
fic
an
t r
ed
uc
tio
n 
in
 m
ea
n 
da
ys
 o
f a
cu
te
[3
1]
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C
lin
ic
al
 T
ri
al
A
nt
io
xi
da
nt
St
ud
y 
A
im
O
ut
co
m
e
R
ef
er
en
ce
br
on
ch
iti
s
re
sp
ira
to
ry
 il
ln
es
s p
er
 p
at
ie
nt
.
A
 d
ou
bl
e–
bl
in
d,
 p
ar
al
le
l-
gr
ou
p 
stu
dy
 in
 th
e 
U
K
 in
10
9 
pa
tie
nt
s w
ith
 ch
ro
ni
c
br
on
ch
iti
s o
ve
r 6
 w
in
te
r
m
o
n
th
s
Ca
rb
oc
ys
te
in
e
Ef
fe
ct
 o
f 7
50
 m
g
ca
rb
oc
ys
te
in
e 
th
re
e 
tim
es
da
ily
 c
om
pa
re
d 
w
ith
pl
ac
eb
o 
on
 p
ea
k 
flo
w
 a
nd
ex
ac
er
ba
tio
n 
ra
te
.
N
o 
sig
ni
fic
an
t d
iff
er
en
ce
 in
 e
xa
ce
rb
at
io
n 
ra
te
.
Si
gn
ifi
ca
nt
 in
cr
ea
se
s i
n 
pe
ak
 fl
ow
 fr
om
 b
as
el
in
e
in
 b
ot
h 
pl
ac
eb
o 
an
d 
in
te
rv
en
tio
n 
gr
ou
ps
[3
2]
R
CT
s i
n 
To
ky
o 
in
 1
56
pa
tie
nt
s w
ith
 C
O
PD
 o
ve
r
a 
12
-m
on
th
 p
er
io
d
Ca
rb
oc
ys
te
in
e
Ef
fe
ct
 o
f 1
.5
 g
ca
rb
oc
ys
te
in
e 
da
ily
 w
ith
pl
ac
eb
o
N
o 
sig
ni
fic
an
t d
iff
er
en
ce
s i
n 
se
ve
rit
y 
of
 C
O
PD
.
Si
gn
ifi
ca
nt
 re
du
ct
io
n 
in
 th
e 
nu
m
be
r o
f c
om
m
on
co
ld
s a
nd
 re
du
ct
io
n 
in
 ra
te
 o
f e
xa
ce
rb
at
io
n
[3
3-
34
]
R
CT
s i
n 
Ja
pa
n 
in
vo
lv
in
g
14
2 
pa
tie
nt
s w
ith
 C
O
PD
co
n
du
ct
ed
 o
ve
r a
 1
2-
m
o
n
th
 p
er
io
d
Ca
rb
oc
ys
te
in
e
Tr
ea
tm
en
t w
ith
 5
00
m
g
ca
rb
oc
ys
te
in
e 
th
re
e 
tim
es
a 
da
y
Co
ns
ist
en
t r
ed
uc
tio
n 
in
 e
xa
ce
rb
at
io
n 
fre
qu
en
cy
.
N
o 
ch
an
ge
 in
 lu
ng
 fu
nc
tio
n
[2
6]
PE
A
CE
 st
ud
y
EQ
UA
LI
FE
 st
ud
ies
Ca
rb
oc
ys
te
in
e
(ca
rbo
cis
tei
ne
)
V
ec
tri
ne
-th
io
l
co
m
po
un
d,
 3
00
m
g
bi
d 
fo
r m
on
th
s
Ef
fe
ct
 o
n 
ra
te
 o
f
ex
ac
er
ba
tio
ns
Ef
fe
ct
 o
n 
ex
ac
er
ba
tio
n
ra
te
, h
os
pi
ta
liz
at
io
n,
 lu
ng
fu
nc
tio
n,
 a
nd
 q
ua
lit
y 
of
lif
e
Lo
ng
-te
rm
 (o
ne
 ye
ar)
 us
e o
f c
arb
oc
ys
tei
ne
 (1
50
0
m
g/
da
y) 
pro
du
ce
d r
ed
uc
tio
n i
n n
um
be
rs 
of
ex
ac
er
ba
tio
ns
 in
 p
at
ie
nt
s w
ith
 C
O
PD
D
ec
re
as
ed
 e
xa
ce
rb
at
io
ns
 a
nd
 fe
w
er
 d
ay
s i
n
ho
sp
ita
l. 
N
o 
lo
ss
 o
f l
un
g 
fu
nc
tio
n 
an
d
im
pr
ov
em
en
t i
n 
he
al
th
-re
la
te
d 
qu
al
ity
 o
f l
ife
[1
7]
[2
3]
BR
ON
CU
S 
=
 B
ro
nc
hi
tis
 R
an
do
m
iz
ed
 o
n 
N
-a
ce
ty
l-L
-c
ys
te
in
e 
Co
st 
U
til
ity
 S
tu
dy
, b
id
= 
Tw
ic
e 
da
ily
; F
EV
1 
=
 F
or
ce
d 
ex
pi
ra
to
ry
 v
ol
um
e 
in
 1
 se
co
nd
, T
BA
RS
 =
 T
hi
ob
ar
bi
tu
ric
 a
ci
d 
re
ac
tiv
e 
su
bs
ta
nc
es
, N
A
C
=
 N
-a
ce
ty
l-L
-c
ys
te
in
e,
 E
BC
 
=
 E
xh
al
ed
 B
re
at
h 
Co
nd
en
sa
te
, R
CT
s: 
Ra
nd
om
iz
ed
 p
la
ce
bo
-c
on
tro
lle
d 
tri
al
s.
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